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Summary Twelve patients with advanced small cell carcinoma of the bronchus were treated by continuous
infusion of recombinant human granulocyte colony-stimulating factor (rhG-CSF) at the following dose levels:
1 jug, 5jug, 10jMg, 20jig and 40pgkg- day-I for 5 days. No toxicities resulted from the treatment and in all
12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100x 1091-1 at
10jgkg-lday- . The neutrophils were shown to be functionally normal in tests of their mobility and
bactericidal activity. During the phase II part of the study the patients were treated by a combination of
intravenous adriamycin 50mg m 2, ifosfamide 5gm-2 by i.v. infusion with mesna 8gm-2 on day 1, and
etoposide 120mgm 2 on days 1, 2 and 3 also intravenously. The chemotherapy regime was repeated every 3
weeks. RhG-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the
period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal,
neutrophil counts within 2 weeks after day 1 of chemotherapy. Six severe infective episodes were observed
during the cycles ofchemotherapy which did not include rhG-CSF, while no infective episodes occurred when
patients were treated with rhG-CSF. These results demonstrate the utility of rhG-CSF in restoring functional
neutrophils to patients undergoing intensive chemotherapy.
In a frequently quoted study by Bodey et al. (1965) the
percentage of days spent with infection in patients with acute
leukaemia treated by cytotoxic therapy increased sharply
when absolute neutrophil counts fell below 1.0 x 109-1,
whereas protection against infection appeared to be fairly
adequate with neutrophil levels above 1.5 x 1091-1. The most
important factor in predicting risk of infection was the
duration of the neutropenia with a 60% risk of developing a
severe infection if neutropenia persisted for 3 weeks. Similar
conclusions were reached in other studies in patients with
solid tumours treated by cytotoxic chemotherapy (Pizzo &
Young, 1985).
Since then, considerable improvements in supportive care
have helped to reduce infection-related morbidity and
mortality, but infection remains the most common cause of
death in chemotherapy treated patients. Several new anti-
microbial agents have become available during the last
decade and it is generally accepted that the initial empiric
management of the febrile neutropenic patient can be
accomplished successfully with a variety of two to three
antibiotic combinations (Hiemenz & Pizzo, 1985), but
patients who remain febrile after one week and those whose
neutrophil count has not risen above 0.5 x 109 1-I remain at
high risk of dying. In the mid 1970s several clinical trials
suggested that neutrophil transfusions would be of help to
such patients but a more recent prospectively controlled trial
with randomized patients (Winston et al., 1982) failed to
show any benefit. This was not only because of improve-
ments in antibiotic therapy but also because of limitations
of leukocyte collection technology. For instance, it has been
estimated that even the most efficient cell separations can
only yield enough cells to cover 5% of the neutrophil
turnover which might be expected in the presence of severe
infection (Young, 1983). Other problems of neutrophil
transfusions include the risk of alloimmunization (not only
to leukocytes but also to platelets), pulmonary toxicity and
transmission of cytomegalovirus (Hiemanz & Pizzo, 1985).
Here we report a novel approach utilizing a recently
molecularly cloned and purified haemopoietic growth factor
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(recombinant human granulocyte colony-stimulating factor,
rhG-CSF, Souza et al., 1986) which we have given by
continuous i.v. infusion to patients receiving intensive
chemotherapy for small cell lung cancer in an attempt to
prevent or reduce their period of neutropenia. The relevant
clinical findings are presented in this paper. The biological
effects in vitro and in vivo of rhG-CSF and their possible
mechanisms will be discussed more fully in a subsequent
paper (Bronchud et al., 1987, submitted).
Materials and methods
Patients
A total of 12 patients are reported (6M; 6F), with a median
age of 65. To be eligible they had to have histologically
confirmed small cell carcinoma of the bronchus and belong
to the intermediate prognostic group according to the
'Manchester score' (Cerny et al., 1987). In this score the
prognostically important pre-treatment variables are: lactate
dehydrogenase, stage of disease, serum sodium, Karnofsky
performance status, serum alkaline phosphatase and serum
bicarbonate. Other eligibility criteria for our study included a
normal pretreatment peripheral blood count (haemoglobin
more than 10gdl-1, total leucocyte count >3 x 10911- and
platelets >100 x 1091-), no prior treatment with biological
response modifiers or chemotherapy, adequate renal function
and normal hepatic function, except if involved by tumour.
The original eligibility criteria included a normal bone
marrow aspirate but the protocol was amended as bone
marrow involvement has been found in up to 69% of
patients with advanced small cell lung cancer (Stahel et al.,
1985) and in our patients it made no significant difference in
terms of bone marrow response to rhG-CSF. Patients were
excluded if they had any of the following: evidence of
continuing infection, known hypersensitivity to E. coli
derived preparations, chronic lung disease with resting hyper-
capnoea, disabling congestive cardiac failure or history of
unstable angina.
An informed consent was obtained from all the
participating patients.
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Clinical and laboratory monitoring
Before and during the course of the study all patients were
monitored by the recording of weight, blood pressure, radial
pulse and oral temperature, physical examination,
determination of the complete blood count (by Coulter
method) with differential and reticulocyte count, full
biochemistry screen (including serum urate and glucose),
measurement of prothrombin time and partial thrombo-
plastin time, creatinine clearance and urinalysis, follow-up
chest X-rays and, if required, isotope liver scans. In addition,
at the start and at the end of the phase-I part of the study,
they underwent a bone marrow aspirate and trephine (for
histological assessment and in vitro clonogenic assays of
haemopoietic progenitor cells) and granulocytes from
peripheral blood were tested for mobility and bactericidal
activity (H. Bronchud et al., 1987, submitted).
Recombinant human G-CSF
Recombinant human G-CSF (rhG-CSF) produced by E. coli
was supplied by AMGen, Thousand Oaks, California. RhG-
CSF purified from E. coli is a single chain polypeptide, not
glycosylated, with a molecular weight of -18.8kD (Souza
et al., 1986). It is formulated in open label vials as a sterile
solution at a concentration of 0.25mgml-1, and each batch
was demonstrated to be biologically active and free from
pyrogens before release. It was administered to patients as a
continuous infusion via a central venous line in 5% glucose
and 0.2% human serum albumin (BPL, Elstree), to avoid
non-specific binding to the plastic, loaded into the reservoir
of a Pharmacia infusion pump (CADD-1TM model,
Pharmacia, USA) which was programmed for a variable
number of days (depending on the particular dose level of
each patient) so that there was no risk of the pump running
out of drug. The central line was inserted in either the right
or the left subclavian vein. We used the silicone catheters
Nutricath 'S' (Vygon, France) introduced, under local
anaesthetic, by the Seldinger technique. A 3 to 4cm long
subcutaneous tract was fashioned and the catheter was
sutured in place and left in-dwelling as long as it could be
maintained. It was flushed with 100 units heparin solution
on a weekly basis and a sterile dressing was also applied
once or twice weekly. There were no complications from the
insertion of central venous lines.
Cytotoxic chemotherapy
All patients who went onto the phase II part of the study
received the following chemotherapy: Ifosfamide 5 gm2,
mesna 8 gm-2 and adriamycin 50 mgm-2 on day 1, and
etoposide 120mgm-2 on days 1, 2 and 3. This regime was
already being used in our Department in patients with small
cell lung cancer and was known to cause WHO grade 4
leucopenia in 40% of patients but was accompanied by an
overall response rate of 83% including both partial and
complete remissions (Lind et al., 1987). Chemotherapy cycles
were repeated every 3 weeks up to a total of 6.
Study design
This was an open-label study in which, whenever possible,
each patient participated in a phase I and phase II study.
The phase I part of the study consisted of a 5 day
continuous infusion of rhG-CSF to assess toxicity and effect
on bone marrow and peripheral blood counts, followed by 2
days off rhG-CSF to allow the peripheral neutrophil count
to return to normal levels prior to chemotherapy. Patients
were entered in pairs sequentially at the following dose levels
of rhG-CSF: 1lpg, 5,ug, lOg, 20 pg and 40pgkg 1day-1.
There was no dose escalation within a patient and each patient
who went onto the phase II part of the study acted as
his/her own control, receiving rhG-CSF after alternate
courses of cytotoxic chemotherapy, at the same dose as used
in the phase I. Patients were assigned sequentially to receive
rhG-CSF on odd or even chemotherapy cycles. Any patient
unable to progress to the phase II was replaced by another
patient at the same dose level of rhG-CSF and was identified
by adding R (for 'replacement') to his/her study number.
RhG-CSF was started 24h after the last dose of i.v.
etoposide to allow adequate clearance of cytotoxics from the
circulation and it was continued for a total of 14 days. No
rhG-CSF was given for 3 days prior to the following course
of chemotherapy to allow a normalisation of the neutrophil
count. If the peripheral white cell count exceeded 100 x 109
cells I1- the dose of rhG-CSF was reduced by 50% to avoid
possible complications from leucostasis.
The study protocol was approved by the district medical
ethics committee.
Statistics
Absolute neutrophil counts (at day 15 of each chemotherapy
cycle) when on and off rhG-CSF were analysed by the
Wilcoxon matched-pairs signed-ranks test. The total period
of absolute neutropenia (peripheral neutrophil count
<1 x 1091-) on and off rhG-CSF was calculated for each
patient and for each cycle of chemotherapy from the total
area below the 1 x 1091-1 level (shaded areas in Figures
2a-d) by a computer programme written for this purpose.
The number of severe infections on and off rhG-CSF
requiring admission to hospital for i.v. antibiotics was
analyzed by the Fisher's exact test.
Results
During the phase I part of the study all 12 patients
responded to rhG-CSF with a rapid increase of their
peripheral neutrophil counts to a maximum of 100 x 1091 -
in patient 5 at 10pgkg - day-1. As shown in Figure la-c
there was considerable overlap in the absolute neutrophil
count for all dose levels of rhG-CSF, although the lowest
counts were seen at 1 pgkg-1 day-1. RhG-CSF did not
affect the peripheral counts of monocytes, platelets,
lymphocytes or eosinophils.
Two patients (nos. 5 and 8) could not enter the phase II
part of the study because of rapidly advancing disease and
poor general state. A third patient (no. 7) with very
advanced disease died suddenly from respiratory failure
following her first course of chemotherapy. The remaining 9
patients all had a minimum of 2 courses of chemotherapy
following the phase I part of the study. Some examples of
their haematological responses are shown in Figure 2.
Patient 1 (Figure 2a) received I pgkg-1 day- I of rhG-CSF
following chemotherapy cycles 1 and 3, and died following
cycle 4 (while not on rhG-CSF) severely neutropenic after a
short illness with intermittent pyrexia, sudden onset left
hemiparesis and heart failure and gastrointestinal bleeding as
terminal events. Post-mortem examination confirmed
residual lung cancer, large vegetations of endocarditis
(presumably bacterial) destroying the two posterior cusps of
the aortic valve and 'embolic' infarcts in both kidneys,
spleen, brain and probable ischaemic enterocolitis.
Patient 2, also received 1 pgkg-1 day-1 of rhG-CSF and
has now completed the full 6 courses of chemotherapy with
virtually no neutropenia while on rhG-CSF. Figure 2b shows
the first 4 cycles and his haematological profile was similar
during the last 2. Patient 3 (Figure 2c) avoided neutropenia
altogether following the third cycle of chemotherapy while
on rhG-CSF, and showed a remarkable bone marrow
recovery throughout. Although he became transiently
neutropenic following his first chemotherapy (on rhG-CSF)
his absolute neutrophil count went up from 0.1 x 109 1-1 to
100 x 10 1-1 in just 3 days and following his second course
of chemotherapy (off rhG-CSF) he required i.v. antibiotics
while severely neutropenic.
Patient 5R, on 1Opgkg-1 day-1 of rhG-CSF, had received
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Figure 1 Dose-response of rhG-CSF during the phase I part of
the study. Absolute neutrophil counts (x 104cellsmm-3) before
and during the growth factor infusion are shown. (a): response to
l gkg-'day-
' in patients 1 (0) and 2 (E) and to
5Mgkg-day-I in patients 3 (0) and 4 (El). (b): response to
l10gkg-l day-I in patients 5 (0), 5R (Oll) and 6 (A\). (c):
response to 20 gkg -day - in patients 7 (0), 7R (0), 8 (-),
8R (Cl) and response to 40pgkg- day-1 in patient 9 (A). The





Figure 2 Haematological response to rhG-CSF during the phase
I and after chemotherapy (CT) in patients 1, (a), 2, (b) (both at
Ilgkg- I day- I of rhG-CSF); 3, (c) (at 5 pgkg-1 day-1) and 5R,
(d) (at 10pgkg-l day-l). BT: blood transfusion. The shaded
areas represent the total area of absolute neutropenia.
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prior to chemotherapy and her bone marrow was extensively
replaced histologically by small cell carcinoma. In spite of
this she showed a very good response to rhG-CSF with
virtually no neutropenia while receiving the preparation, and
severe neutropenia while not. Figure 2d shows her first 2
cycles of chemotherapy. She behaved in a similar fashion
during cycles 3 and 4. Her platelet count decreased
considerably after chemotherapy, whether or not she was on
rhG-CSF at the time.
Five other patients have shown qualitatively and
quantitatively similar responses to rhG-CSF following
chemotherapy to those documented in Figure 2a-d with a
reduction in the neutropenia in all cases.
Discussion
The phase I part of our study resulted in a striking increase
in absolute neutrophil counts (Figure 1) in response to rhG-
CSF without any appreciable change in platelets, lymphocyte
counts or haemoglobin. Also. there were no significant
changes in monocytes or eosinophils. This is in contrast to a
recent report of recombinant human GM-CSF in humans,
where the number of peripheral eosinophils often exceeded
the number of peripheral neutrophils (Groopman et al.,
1987) and presumably reflects the different target cells
promoted by these two growth factors. Furthermore, the
effects of rhG-CSF on neutrophil recruitment seen in our
patients is similar in magnitude to that observed in animals
(Welte et al., 1987; Moore et al., 1987a,b), indicating the
predictive value of these pre-clinical test systems. An
important question which arises is whether or not the
neutrophils are functionally competent. Significantly, in our
study we have found that the peripheral neutrophils during
the phase I part of the study showed normal mobility and
bactericidal activity. This was also true for neutrophils
obtained after recovery from cytotoxic-induced neutropenia
and will be discussed in more detail in a subsequent paper
(H. Bronchud et al., 1987, submitted). No clinical toxicities
were seen in any of the treated patients and, in particular,
there were no febrile episodes related to rhG-CSF therapy,
'flu-like' symptoms or changes in blood pressure. The only
biochemical changes detected were an increase in the total
lactic dehydrogenase activity in serum (sometimes
>103IUI-1) in parallel with the increase in neutrophil
numbers and a similar, but milder, change in total alkaline
phosphatase activity. As all the other biochemical indices
remained normal (including liver and bone indices) we
presume that these changes directly reflected the considerable
increase in peripheral granulocytes.
In the phase II part of the study there was a prompt
recovery in the post-chemotherapy fall of neutrophil counts
with a marked difference by day 15 between the cycles with
rhG-CSF and those without. Table I shows the data for the
first 6 patients with a P value of <0.01. The percentage
reduction of the total absolute neutropenia with rhG-CSF
was 80% (median, with a range of 52-100%). Although
there was some individual variation, an adequate reduction
in neutropenia was seen with 1 to 40pgkg-1 day-1, but the
neutrophilia following recovery from neutropenia was more
pronounced at 5-40Mgkg-1 day-1. Qualitatively similar, but
Table I Absolute neutrophil counts at day 15.
Patient On rhG-CSF OffrhG-CSF
1 12000 (6000-18000) 211 (72-350)
2 27000 (40000-14000) 400 (100-700)
3 78637 (77274-80000) 295 (190-400)
4 7000* 145 (70-220)
5R 45000 108
6 18900 1100
Patients 1 and 2 received l gkg-lday-1 of rhG-
CSF for 14 days after cycles 1, 3 and 2, 4 respectively;
patients 3 and 4 received 5 gkg-1 day-1 of rhG-CSF
for 14 days after cycles 1, 3 and 2 respectively; patients
SR and 6 received lOgkg-lday-a of rhG-CSF for
14 days after cycles 1 and 2 respectively. (*rhG-CSF
pump did not function for a period of48-72h).
more pronounced, responses to rhG-CSF have also been
observed in animals undergoing recovery from treatment
with cyclophosphamide (Welte et al., 1987). Such data
indicate the potential usefulness of this growth factor for
alleviating the myelotoxicity of cytotoxic agents used in a
variety ofchemotherapy regimes.
Of major significance in this regard were the effects seen
on infective episodes in our patients. There were six severe
infective episodes while off rhG-CSF (with one documented
coliform septicaemia and one documented coagulase-negative
staphilococcal septicemia) requiring a total of 30 days in
hospital for i.v. antibiotics. In contrast, no infective episodes
were seen while on rhG-CSF. This difference was statistically
significant (P=0.012). Two of the 12 patients have now
completed their six courses of chemotherapy and are in
clinical complete remission.
It should be noted that our protocol, using continuous
infusion of growth factor, was designed to maintain the
circulating levels of rhG-CSF at a constant value since in
vitro evidence indicates that optimal response of
haemopoietic cells to growth factors requires their
continuous presence (Metcalf & Foster, 1967). Similar
findings in vivo are indicated by our phase I study which
clearly showed a rapid fall in circulating neutrophils to
normal levels within 24 to 48h after stopping the growth
factor infusion. Other studies in animal systems have also
shown that repeated injections (i.v. or s.c.) of growth factors
are effective at recruiting haemopoietic cells (Welte et al.,
1987; Moore et al., 1987b). Nonetheless, the clinical efficacy
of different routes of administration will require further
examination.
In conclusion, recombinant human G-CSF appears to be
well tolerated by patients and to considerably reduce the
neutropenia and severe infections caused by intensive
chemotherapy.
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